[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649925":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":34,"studyPopulation":34,"armGroups":41,"interventions":52,"overallOfficials":58,"centralContacts":62,"locations":68,"responsibleParty":125,"collaborators":34,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":34,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":34,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":34,"overallStatus":71,"whyStopped":34,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":24,"otherOutcomes":34},[9,13,17,21],{"measure":10,"description":11,"timeFrame":12},"Part 1: Area Under the Concentration Time Curve From Time 0 to 4 Weeks (AUC0-4w) of MK-1406","Blood samples will be collected at pre-specified timepoints to determine the AUC0-4w of MK-1406.","Predose and at designated timepoints up to 4 weeks postdose",{"measure":14,"description":15,"timeFrame":16},"Part 1 and Part 2: Number of Participants Who Experience One or More Adverse Events (AEs)","An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.","Up to approximately 43 days postdose",{"measure":18,"description":19,"timeFrame":20},"Part 1 and Part 2: Number of Participants Who Experience At Least One Solicited Injection-Site Reaction","Solicited injection-site reactions include tenderness, pain, redness\u002Ferythema, and swelling. Participants will record injection site reactions using a paper diary. The number of participants with solicited injection-site reactions will be reported.","Up to approximately 7 days postdose",{"measure":22,"description":23,"timeFrame":16},"Part 1 and Part 2: Number of Participants Who Discontinue Study Due to an AE","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.",[25,28,31],{"measure":26,"description":27,"timeFrame":12},"Part 1: Maximum Plasma Concentration (Cmax) of MK-1406","Blood samples will be collected at pre-specified timepoints to determine the Cmax of MK-1406.",{"measure":29,"description":30,"timeFrame":12},"Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-1406","Blood samples will be collected at pre-specified timepoints to determine the Tmax of MK-1406.",{"measure":32,"description":33,"timeFrame":12},"Part 1: Plasma Concentration of MK-1406 at 4 Weeks (C4w)","Blood samples will be collected at pre-specified timepoints to determine the C4w of MK-1406.",null,{"allocation":36,"interventionModel":37,"interventionModelDescription":34,"primaryPurpose":38,"observationalModel":34,"timePerspective":34,"maskingInfo":39},"RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":40,"maskingDescription":34,"whoMasked":34},"NONE",[42,48],{"label":43,"type":44,"description":45,"interventionNames":46},"MK-1406 3-Injections","EXPERIMENTAL","Participants receive 3 subcutaneous (SQ) injections of MK-1406 on Day 1.",[47],"Drug: MK-1406",{"label":49,"type":44,"description":50,"interventionNames":51},"MK-1406 2-Injections","Participants receive 2 SQ injections of MK-1406 on Day 1.",[47],[53],{"type":54,"name":55,"description":56,"armGroupLabels":57,"otherNames":34},"DRUG","MK-1406","Subcutaneous administration",[49,43],[59],{"name":60,"affiliation":5,"role":61},"Medical Director","STUDY_DIRECTOR",[63],{"name":64,"role":65,"phone":66,"phoneExt":34,"email":67},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[69,87,99,112],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"Research Centers of America ( Hollywood ) ( Site 0008)","RECRUITING","Hollywood","Florida","33024","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-80.14949,26.0112,{"lat":81,"lon":80},[84],{"name":85,"role":65,"phone":86,"phoneExt":34,"email":34},"Study Coordinator","954-990-7649",{"facility":88,"status":71,"city":89,"state":73,"zip":90,"country":75,"countryCode":76,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"QPS-MRA, LLC ( Site 0007)","South Miami","33143",{"type":78,"coordinates":92},[93,94],-80.29338,25.7076,{"lat":94,"lon":93},[97],{"name":85,"role":65,"phone":98,"phoneExt":34,"email":34},"305-722-0970",{"facility":100,"status":71,"city":101,"state":102,"zip":103,"country":75,"countryCode":76,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Hassman Research Institute Marlton Site ( Site 0001)","Marlton","New Jersey","08053",{"type":78,"coordinates":105},[106,107],-74.92183,39.89122,{"lat":107,"lon":106},[110],{"name":85,"role":65,"phone":111,"phoneExt":34,"email":34},"856-452-9901",{"facility":113,"status":71,"city":114,"state":115,"zip":116,"country":75,"countryCode":76,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Velocity Clinical Research, Cleveland ( Site 0005)","Cleveland","Ohio","44122",{"type":78,"coordinates":118},[119,120],-81.69541,41.4995,{"lat":120,"lon":119},[123],{"name":85,"role":65,"phone":124,"phoneExt":34,"email":34},"216-682-0320",{"type":126,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100649925","phase-1-a-clinical-trial-of-mk-1406-in-healthy-participants-mk-1406-008-100649925",false,"NCT07743151","A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)","A Randomized, Open Label, Parallel Group Phase 1 Study to Compare Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MK-1406 as Three Injections Compared With Two Injections in Healthy Adult Participants","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health\n* Has body mass index (BMI) 18.0 to 32.0 kg\u002Fm\\^2\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases\n* History of cancer (malignancy)",true,"ALL","18 Years","64 Years",{"count":139,"type":140},400,"ESTIMATED","INTERVENTIONAL",[143],"PHASE1","The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.",[146],"Healthy","2026-10-02",{"date":149,"type":150},"2026-10-05","ACTUAL",{"date":152,"type":150},"2026-09-10",{"date":154,"type":140},"2027-02-05",{"name":5,"class":6},4]